Kidney cancer (Canada)
About this PSP
In 2014, a PSP was set up by the Kidney Cancer Research Network of Canada to determine the research priorities of Canadian Kidney Cancer Patients, Caregivers and Clinicians.
The video below shows Michael Jewett talking about the PSP.
Top 10 priorities
- What are the treatment options for patients with advanced non-clear cell renal cell carcinoma (kidney cancer)?
- Are there measurable, biological indicators (biomarkers) that can be used to predict the response to a treatment?
- Are there measurable, biological indicators (biomarkers) for the detection of kidney cancer?
- Can we develop better therapies that use the immune system to fight cancer (immunotherapies) including biomarkers, immune markers of patient, tumour characteristics and response?
- What indicators can be used to predict the development and progression of metastatic kidney cancer?
- How can psychological, emotional and social support be best given to patients and their families?
- Can decision making tools be developed that help both patients and healthcare providers to make treatment decisions in advanced/metastatic disease?
- What is the role and criteria for using biopsy in the management of kidney cancer?
- Does our government funding structure reflect outcomes of our kidney cancer patients compared to the rest of the world?
- What causes kidney cancer (including risk factors and dietary causes)?